Nls pharmaceutics announces open label extension study six-month data for quilience(r) (mazindol er) in the treatment of narcolepsy type 1 and type 2

Patients treated with mazindol er in the randomized phase 2 trial showed continued improvement after rolling over into the open label extension (ole) study patients treated with placebo in the randomized phase 2 trial and who subsequently received mazindol er in the ole study achieved comparable results to the mazindol er-treated patients in the phase 2 trial safety and tolerability of mazindol er were similar between the randomized trial and the ole study once-daily monotherapy with mazindol er shows potential to meet the unmet needs of currently available narcolepsy treatment options zurich, switzerland / accesswire / march 27, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the final results from its open label extension (ole) study for quilience® (mazindol er) in the treatment of narcolepsy.
NLSP Ratings Summary
NLSP Quant Ranking